Genitourinary Cancers | Specialty

How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation Process

October 21st 2014

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

Petrylak Anticipates Bright Future for PD-L1 Inhibitors in Bladder Cancer

October 9th 2014

Checkpoint inhibitors targeting the PD-1 receptor and its ligand, PD-L1, are showing efficacy in early-phase clinical trials in urothelial bladder cancer, generating the promise of new therapies for a disease that has not had a significant treatment advance in 30 years.

Commercial Tests Offer Guidance in Bladder, Renal, Testicular Cancers

October 7th 2014

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma

October 6th 2014

Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma

Durable Responses Observed with Nivolumab in Previously Treated mRCC

September 30th 2014

Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

September 30th 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

Robotic Prostatectomy Rises, and So Do Costs: Study Tracks Patterns

September 17th 2014

Robotic-assisted radical prostatectomy (RARP) was widely adopted in the United States between 2003 and 2010, mainly among high-volume surgeons.

A Call to Arms

September 8th 2014

The year was 1989, and I was one year away from finishing six years of residency in general surgery and urology.

Urology Clinics Must Lead Way in Preventing Workplace Violence

August 29th 2014

It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.

Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer

August 27th 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

Dr. Parsons Discusses the Link Between Exercise and Bladder Cancer Risk

August 25th 2014

J. Kellogg Parsons, MD, associate professor of surgery (urology), University of California, San Diego, discusses modifiable lifestyle factors associated with bladder cancer.

Genes That Drive Clear-Cell RCC Discovered, Providing Research Clues

August 21st 2014

A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.

In 2 Cancers, Robotic Versus Open Surgery is Explored

August 20th 2014

In recent studies, robotic-assisted surgery was explored as a treatment for both prostate and kidney cancers.

It's Not About the Organ

July 24th 2014

I am sure that those of you who attended the AUA meeting in Orlando were struck by the number of presentations on the use of biomarkers and their role in better risk stratification and management of the urologic oncology patient.

Dr. Hutson Discusses the Phase III ATLAS Study in RCC

July 18th 2014

Thomas E. Hutson, DO, PharmD, medical oncologist, Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses the rationale behind the ATLAS Study, a randomized double-blind phase III study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Advanced Prostate Cancer Clinics Keep Urologists, Patients Together

July 10th 2014

When a patient develops advanced prostate cancer, that doesn't mean his urologist needs to bid him farewell.

Changing Treatment Landscape for RCC

June 25th 2014

Palliative Care for Patients With RCC

June 25th 2014

Role of TKIs in Oligometastatic RCC

June 25th 2014